PaulAHamlinMD

PubMed

• 36 citations
  Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-Era
  Sabela Bobillo, Erel Joffe, Jessica A. Lavery, David Sermer, Paola Ghione
  Blood. 2021-01-07
• 90 citations
  Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
  Connie Lee Batlevi, Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith
  Blood Cancer Journal. 2020-07-17
• 16 citations
  Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?
  Brandon S. Imber, K. Chau, Jasme Lee, Jisun Lee, Dana L. Casey
  Blood Advances. 2021-10-26

Abstracts/Posters

• Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with Rituximab
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  Paul A. Hamlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Aging and Hematologic Disorders: Exploring the Evidence 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018